Quick orientationEvidence update: 6 October 2026
What is Thymosin Alpha-1?
Thymosin Alpha-1, also called thymalfasin, is a 28-amino-acid peptide studied for immune regulation. It interacts with several parts of immune signalling, including dendritic cells, T-cell responses and innate immune pathways.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Condition-specific human trials include infectious disease, oncology adjunct settings and immune dysfunction, with varying results.
What the mechanism suggests
Immune-modulating peptide (thymalfasin) influencing innate/adaptive immune signalling.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Immune-modulating peptide (thymalfasin) influencing innate/adaptive immune signalling.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
TESTS Phase 3 sepsis trial — BMJ 2025
Multicentre double-blind Phase 3 · 1,106 adults with sepsis28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo; hazard ratio 0.99 and p=0.93. No secondary or safety outcome differed significantly.
A large modern trial is more informative than older encouraging signals: this one did not show an overall mortality benefit in sepsis.
What it doesn't prove: One disease setting; does not settle every proposed immune indication.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Chronic hepatitis B RCT | 1.6 mg SC twice weekly | 6 months | Fixed | Human randomized study |
| HBV pilot — low/high | 0.8 or 1.6 mg SC six times/week ×2 weeks, then twice weekly | 24 weeks | Intensive lead-in → twice weekly | Human pilot |
| HBV acute-on-chronic liver | 1.6 mg SC daily week 1, then twice weekly | 12 weeks | Daily → twice weekly | Human randomized trial |
| failure | weeks 2–12 | |||
| Dialysis/COVID prevention pilot | 1.6 mg SC twice weekly | 8 weeks | Fixed | Human randomized pilot |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Common community/clinic | 1.6 mg SC twice weekly | 8–24 weeks | Usually fixed | Mirrors common clinical literature |
| More frequent community | ~1.5–3 mg per dose, 2×/week to daily depending goal/source | Variable | No universal titration | Community/off-label |
Unlike many compounds on PP, thymalfasin has substantial human dosing experience, but approvals and indications vary by country. The familiar 1.6 mg twice-weekly schedule has genuine clinical-study precedent.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Evidence depends strongly on condition; approvals vary internationally.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
A large modern trial is more informative than older encouraging signals: this one did not show an overall mortality benefit in sepsis.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.